ADENOVIRUS IL-12 AND DOCETAXEL IN COMBINATION WITH ANTI-PD1 AS AN EFFECTIVE TREATMENT STRATEGY FOR TNBC

被引：0
|
作者：
Qian, Wei [1 ]
Zhou, Jianying [1 ]
Rosato, Roberto [1 ]
Chang, Jenny [1 ]
Anselme, Ann [1 ]
机构：
[1] Houston Methodist Res Inst, Houston, TX USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0437
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
437
引用
收藏
页码：A266 / A266
页数：1
相关论文
共 50 条
  • [21] Pulsed electrical fields in combination with anti-PD1 and survival of mice with TNBC (EMT6) murine breast tumor.
    Nafie, Ebtesam
    Pastori, Chiara
    Wagh, Mukta
    Murad, Fatima
    Trikha, Mohit
    Neal, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy
    Dearden, Helen Clare
    Au, Lewis
    Wang, Daniel Ying
    Zimmer, Lisa
    Eroglu, Zeynep
    Smith, Jessica Louise
    Curvietto, Marcello
    Khoo, Chloe
    Atkinson, Victoria
    Lo, Serigne
    Guminski, Alexander
    Long, Georgina V.
    Sandhu, Shahneen Kaur
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Johnson, Douglas Buckner
    Larkin, James M. G.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Regulated intratumoral expression of IL-12 in combination with cytotoxic agents as a strategy for the treatment of metastatic breast cancer
    Nemunaitis, J.
    McArthur, H.
    Hudis, C.
    Reed, T.
    Broder, S.
    Lebel, F.
    Barrett, J.
    Lewis, J.
    Norton, L.
    CANCER RESEARCH, 2013, 73
  • [24] Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
    Chiocca, E. Antonio
    Lukas, Rimas Vincas
    Rao, Ganesh
    Barrett, John A.
    Buck, Jill Y.
    Demars, Nathan
    Smith, Amy
    Miao, John
    Zhou, Qiang
    Gelb, Arnold Bruce
    Cooper, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Enhanced Antitumor Efficacy of Oncolytic Adenovirus Co-Expressing IL-12 and shVEGF Combined with Anti-PD-1 in Renal Cell Carcinoma
    Kim, Yunlim
    Yoon, A-Rum
    Yun, Chae-Ok
    Kim, Choung-Soo
    Lim, Bumjin
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [26] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [27] A Novel Combination Treatment of Armed Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Radiotherapy in Murine Hepatocarcinoma
    Kim, Wonwoo
    Seong, Jinsil
    Oh, Hae Jin
    Koom, Woong Sub
    Choi, Kyung-Joo
    Yun, Chae-Ok
    JOURNAL OF RADIATION RESEARCH, 2011, 52 (05) : 646 - 654
  • [28] Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma
    Manson, Guillaume
    Brice, Pauline
    Herbaux, Charles
    Silva, Maria
    Bouabdallah, Krimo
    Deau-Fisher, Benedicte
    Bouteloup, Juliette
    de Collela, Jean Marc Schiano
    Nicolas-Virelizier, Emmanuelle
    Maerevoet, Marie
    Ghesquieres, Herve
    Bastard, Aspasia Stamatoulas
    Antier, Chloe
    Poizeau, Florence
    Dercle, Laurent
    Houot, Roch
    BLOOD, 2019, 134
  • [29] Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
    Manson, Guillaume
    Brice, Pauline
    Herbaux, Charles
    Bouabdallah, Kamal
    Antier, Chloe
    Poizeau, Florence
    Dercle, Laurent
    Houot, Roch
    HAEMATOLOGICA, 2020, 105 (11) : 2664 - 2666
  • [30] The impact of corticosteroid use during anti-PD1 treatment
    Pan, Eva Y.
    Merl, Man Yee
    Lin, Katherine
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (04) : 814 - 822
12345